PRKAR1A is overexpressed and represents a possible therapeutic target in human cholangiocarcinoma. - Wikidata - awgldk - TriplyDB

PRKAR1A is overexpressed and represents a possible therapeutic target in human cholangiocarcinoma.

PRKAR1A is overexpressed and represents a possible therapeutic target in human cholangiocarcinoma.

http://www.wikidata.org/entity/Q54651230

about

The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer Activated macrophages promote Wnt/β-catenin signaling in cholangiocarcinoma cells.Fatty acid extract from CLA-enriched egg yolks can mediate transcriptome reprogramming of MCF-7 cancer cells to prevent their growth and proliferation PRKAR1A is a functional tumor suppressor inhibiting ERK/Snail/E-cadherin pathway in lung adenocarcinoma.Risk biomarkers for assessment and chemoprevention of liver fluke-associated cholangiocarcinoma.Identification of prostate cancer hub genes and therapeutic agents using bioinformatics approach.Molecular targets in glioblastoma.Targeting protein kinase A in cancer therapy: an update.PKA RIα/A-kinase anchoring proteins 10 signaling pathway and the prognosis of colorectal cancer.Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment.Emerging molecular therapeutic targets for cholangiocarcinoma.STATs profiling reveals predominantly-activated STAT3 in cholangiocarcinoma genesis and progression.Identification of a gene signature for discriminating metastatic from primary melanoma using a molecular interaction network approach.Alternative promoter usage and differential expression of multiple transcripts of mouse Prkar1a gene.Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers.A genetic variation associated with plasma erythropoietin and a non-coding transcript of PRKAR1A in sickle cell disease.PRKAR1A overexpression is associated with increased ECPKA autoantibody in liver fluke-associated cholangiocarcinoma: application for assessment of the risk group.Inhibition of endothelial nitric oxide synthase in cholangiocarcinoma cell lines - a new strategy for therapy.Targeting cholangiocarcinoma.Increased EphB2 expression predicts cholangiocarcinoma metastasis.

P2860

Q26751224-8715A931-D853-4B21-B48A-CF6EFE172352 Q35615320-1C34920A-73D7-4E0E-8186-2EF924CCEC12 Q36887069-576DC69D-4B07-4F50-8152-063AC8D4E5DD Q37142057-B84383FA-45C3-41F3-99AD-C2E2DC7960A6 Q37518538-A53E587E-9BCA-40C1-8584-78F26C64B775 Q38177241-79BD78FD-D61B-464F-B254-8D13D631BE20 Q38429979-AF243EDF-97DC-47DF-A268-7123F95C78E0 Q38465854-892A97E5-633A-4E1A-B4DF-A1653BC23323 Q38594971-7EACF6AC-3E24-4004-89E4-84D1E9A96F13 Q38957357-93929159-3DE3-476F-8D02-A7AAC1B72869 Q39129195-99FDF08C-5C1D-43BD-9082-B146ACDA22CC Q39132926-26C77C2B-DF14-4707-BE88-3A11DCE00B97 Q39227356-758772FB-995C-48C6-AD18-36C3744ABC73 Q45011155-E4BA2149-4F0F-4EB6-80F3-5F036A08A939 Q45943042-247FEF55-9C59-4E2E-8DE2-CB8FC5C0CCAA Q48057741-A7A5D242-F433-49C6-8102-0CDCFEED22EB Q50127508-40F957C8-4A30-4614-831E-2665CF6D2EC1 Q51148340-3CE58CF9-C9C3-4E5C-A1CD-626ABA9AD385 Q51757210-E67093A4-410A-4D35-A22B-D858DCAD955F Q52597485-5034F53B-31BA-49B5-9A67-2FFA930B94A8 Q52757760-F9C7B99C-2402-4848-9BE3-E2C8A2630D13 Q54338851-4B3AC23C-BCFA-4CE4-AEFB-FE7C8CDDB179

P2860

PRKAR1A is overexpressed and represents a possible therapeutic target in human cholangiocarcinoma.

http://www.wikidata.org/entity/Q54651230

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

PRKAR1A is overexpressed and r ...... t in human cholangiocarcinoma.

@en

PRKAR1A is overexpressed and r ...... t in human cholangiocarcinoma.

@nl

type

label

PRKAR1A is overexpressed and r ...... t in human cholangiocarcinoma.

@en

PRKAR1A is overexpressed and r ...... t in human cholangiocarcinoma.

@nl

prefLabel

PRKAR1A is overexpressed and r ...... t in human cholangiocarcinoma.

@en

PRKAR1A is overexpressed and r ...... t in human cholangiocarcinoma.

@nl

P1433

Q54651230-41B4DD8D-476F-485A-B3E7-637609FF894B

P1476

Q54651230-6C44DB0E-1765-47B3-8B42-E5425EB87DB7

P2093

Q54651230-0018838D-3861-429D-86DC-181D03DDE6AC

Q54651230-39A943F9-3359-4BE3-BE2A-551C7B119C56

Q54651230-8698CB0A-7A3B-486E-A743-A136FDF96F70

Q54651230-8BCA5795-AAC8-44A2-8259-02D5D632A071

Q54651230-C73D66ED-8395-405D-9FA7-84B0AE059B31

Q54651230-CA4D6D03-8FDE-4F9B-8F28-CCDBC2024FAC

Q54651230-D6E3350E-2890-46F4-8015-00CF0B832838

P2860

Q54651230-13F5238B-0669-4E65-9491-3AE4C5407AF2

Q54651230-14E3B69E-47F2-4CDA-B85D-A16E9F103998

Q54651230-1867321C-2216-4F5D-B985-20740FD835CE

Q54651230-1983EDFA-E3D4-4D41-A26A-219030DCCDAD

Q54651230-218C5687-9851-408D-9AB9-76760ACB381B

Q54651230-2CE1D599-564D-43CC-8048-77BA511185F1

Q54651230-2E40B57C-B204-4254-BAB6-655EDE8AF458

Q54651230-42670F5A-637B-4E28-A0D6-242432B1ED45

Q54651230-44275986-30D0-45A6-9478-FD3E2F01114A

Q54651230-44941C35-088F-4609-98CB-72DD18D4E577

P304

Q54651230-8863D039-BDEA-47BA-AE32-41E5B6F12C4B

P31

Q54651230-90F2A81D-E90B-4F5C-918F-C2EF34AB5A1A

P356

Q54651230-3169F470-88C7-4EC6-88C5-A8ACC36151BF

P433

Q54651230-E0745BA7-7928-4293-BDB4-2558147904FB

P478

Q54651230-3F605898-FC8D-4CFC-9315-C3B96F64A326

P50

Q54651230-003B149A-A152-43B1-88D2-D7D0C9968851

Q54651230-07CE7C2C-8DC5-4B13-91D2-1235DAE1682B

Q54651230-841E3572-A57A-49A2-A2B0-92294A30A3E4

P577

Q54651230-286608CC-8B8E-45A9-8AB0-8FEDF1CC52B3

P5875

Q54651230-C25F5892-B327-4D2D-9CC3-A919F41140E7

P698

Q54651230-A4AAAE61-2D5D-45B4-A217-7E5C180CBE2B

P921

Q54651230-46214E78-6EC1-4323-856F-728BF38700AA

Q54651230-5B19C7FC-A9E5-4236-BC74-C9113C46047B

P356

P1433

International Journal of Cancer

P1476

PRKAR1A is overexpressed and r ...... t in human cholangiocarcinoma.

@en

P2093

Anucha Puapairoj

http://www.w3.org/2001/XMLSchema#string

Gregory J Riggins

http://www.w3.org/2001/XMLSchema#string

Hideyuki Saya

http://www.w3.org/2001/XMLSchema#string

Masanao Miwa

http://www.w3.org/2001/XMLSchema#string

Nisana Namwat

http://www.w3.org/2001/XMLSchema#string

Sirinun Juntana

http://www.w3.org/2001/XMLSchema#string

Vajarabhongsa Bhudhisawasdi

http://www.w3.org/2001/XMLSchema#string

P2860

Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells

Specificity and mechanism of action of some commonly used protein kinase inhibitors

JAK/STAT-dependent gene regulation by cytokines.

Biliary tract cancers.

Antisense DNA-targeting protein kinase A-RIA subunit: a novel approach to cancer treatment.

Cancer control in Thailand.

Cholangiocarcinoma.

PKB/AKT: functional insights from genetic models.

Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice.

The many faces of H89: a review.

P304

34-44

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.25646

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

129

http://www.w3.org/2001/XMLSchema#string

P50

Puangrat Yongvanit

Watcharin Loilome

P577

2010-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46171415

http://www.w3.org/2001/XMLSchema#string

P698

20824711

http://www.w3.org/2001/XMLSchema#string

P921

cholangiocarcinoma